



Chiara Zecca

Kontakt

Chiara Zecca

Publikationen (16)

Gantenbein A, Bonvin C, Kamm C, Schankin C, Zecca C, Zieglgänsberger D, Merki-Feld G, Pohl H, Rudolph N, Ryvlin P, Agosti R, Schäfer E, Meyer I, Kulartz-Schank M, Arzt M. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. *J Neurol* 2024

Cagol A, Benkert P, Melie-Garcia L, Schaedelin S, Leber S, Tsagkas C, Barakovic M, Galbusera R, Lu P, Weigel M, Ruberte E, Radue E, Yaldizli O, Oechtering J, Lorscheider J, D'Souza M, Fischer-Barnicol B, Müller S, Achtnichts L, Vehoff J, Giulio D, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb J, Remonda L, Wagner F, Vargas M, Du Pasquier R, Lalive P, Pravatà E, Weber J, Cattin P, Absinta M, Gobbi C, Leppert D, Kappos L, Kuhle J, Granziera C. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS. *Neurology* 2023; 102:e207768.

Abdelhak A, Benkert P, Schaedelin S, Boscardin W, Cordano C, Oechtering J, Ananth K, Granziera C, Melie-Garcia L, Montes S, Beaudry-Richard A, Achtnichts L, Oertel F, Lalive P, Leppert D, Müller S, Henry R, Pot C, Matthias A, Salmen A, Oksenberg J, Giulio D, Zecca C, D'Souza M, Du Pasquier R, Bridel C, Gobbi C, Kappos L, Hauser S, Cree B, Kuhle J, Green A, UCSF, MS EPIC, and the SMC Study Teams. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis. *JAMA Neurol* 2023

Meier S, Willems E, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, Cagol A, Barakovic M, Galbusera R, Subramaniam S, Barro C, Abdelhak A, Thebault S, Achtnichts L, Lalive P, Müller S, Pot C, Salmen A, Giulio D, Zecca C, D'Souza M, Orleth A, Khalil M, Buchmann A, Du Pasquier R, Yaldizli O, Derfuss T, Berger K, Hermesdorf M, Wiendl H, Piehl F, Battaglini M, Fischer U, Kappos L, Gobbi C, Granziera C, Bridel C, Leppert D, Maceski A, Benkert P, Kuhle J. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. *JAMA Neurol* 2023; 80:287-297.

Todea A, Melie-Garcia L, Barakovic M, Cagol A, Rahmanzadeh R, Galbusera R, Lu P, Weigel M, Ruberte E, Radue E, Schaedelin S, Benkert P, Oezguer Y, Sinnecker T, Müller S, Achtnichts L, Vehoff J, Disanto G, Findling O, Chan A, Salmen A, Pot C, Lalive P, Bridel C, Zecca C, Derfuss T, Remonda L, Wagner F, Vargas M, Du Pasquier R, Pravatà E, Weber J, Gobbi C, Leppert D, Wuerfel J, Kober T, Marechal B, Corredor-Jerez R, Psychogios M, Lieb J, Kappos L, Cuadra M, Kuhle J, Granziera C. A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients. *J Magn Reson Imaging* 2023

Achtnichts L, Zecca C, Findling O, Kamm C, Müller S, Kuhle J, Lutterotti A, Gobbi C, Viviani C, Villiger-Borter E, Nedeltchev K. Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS). *BMJ Neurol Open* 2023; 5:e000304.

Friedli C, Salmen A, Achtnichts L, Derfuss T, Gobbi C, Kuhle J, Lalive P, Müller S, Papadopoulou A, Pot C, Zecca C, Chan A, Kamm C. Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022. *Clinical and Translational Neuroscience* 2022

Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea R, Rahmanzadeh R, Galbusera R, Lu P, Weigel M, Melie-Garcia L, Ruberte E, Siebenborn N, Battaglini M, Radue E, Yaldizli O, Oechtering J, Sinnecker T, Lorscheider J, Fischer-Barnicol B, Müller S, Achtnichts L, Vehoff J, Giulio D, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb J, Remonda L, Wagner F, Vargas M, Du Pasquier R, Lalive P, Pravatà E, Weber J, Cattin P, Gobbi C, Leppert D, Kappos L, Kuhle J, Granziera C. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. *JAMA Neurol* 2022; 79:682-692.

Oechtering J, Naegelin Y, Maceski A, Meier S, Berger K, Wiendl H, Lincke T, Lieb J, Yaldizli O, Sinnecker T, Derfuss T, Regeniter A, Zecca C, Gobbi C, Kappos L, Granziera C, Leppert D, Kuhle J, Conen D, Aeschbacher S, Subramaniam S, Schaedelin S, Benkert P, Müller S, Achtnichts L, Vehoff J, Giulio D, Findling O, Fischer-Barnicol B, Orleth A, Chan A, Pot C, Barakovic M, Rahmanzadeh R, Galbusera R, Heijnen I, Lalive P, Wuerfel J, Swiss Multiple Sclerosis Cohort Study. Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. *Ann Neurol* 2021; 90:477-489.

Gantenbein A, Agosti R, Gobbi C, Flügel D, Schankin C, Viceic D, Zecca C, Pohl H. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study. *Cephalalgia* 2021; 41:1181-1186.

Rodgers S, Calabrese P, Ajdacic-Gross V, Steinemann N, Kaufmann M, Salmen A, Manjaly Z, Kesselring J, Kamm C, Kuhle J, Chan A, Gobbi C, Zecca C, Müller S, von Wyl V. Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?. *J Psychosom Res* 2021; 144:110402.

Achtnichts L, Salmen A, Chan A, Czaplinski A, Derfuss T, Du Pasquier R, Findling O, Gobbi C, Zecca C, Müller S, Kamm C, Kuhle J, Lalive P, Martin R, Pot C, Papadopoulou A. Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. *Clinical and Translational Neuroscience* 2019

Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J, Swiss Multiple Sclerosis Cohort Study Group. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. *Ann Neurol* 2017; 81:857-870.

Zhang K, Arcuti S, Brunetti M, Moglia C, Calvo A, Ratti A, Tiloca C, Gellera C, Pensato V, Mazzini L, Capozzo R, Zecca C, Blair I, Stuit R, Muller B, Filosto M, Padovani A, Riva N, Penco S, Lunetta C, Sorarù G, Bertolin C, Blauw H, Curtis C, Hofman A, Estrada K, Rivadeneira F, Uitterlinden A, Dartigues J, Tzourio C, Amouyel P, van der Kooij A, de Visser M, D'Alfonso S, Comi G, Del Bo R, Cereda C, Pansarasa O, Smith B, Shaw C, Weber M, Goris A, Nöthen M, McCann E, Veldink J, Corcia P, Andersen P, Hardiman O, Landers J, Glass J, Brown R, Pers T, Franke L, Van Damme P, Vourc'h P, Silani V, van den Berg L, Al-Chalabi A, Breen G, Lewis C, Pasterkamp R, van Es M, de Bakker P, Visscher P, Wray N, Robberecht W, Weishaupt J, Stubendorff B, Prell T, Ringer T, Witte O, Grosskreutz J, Kiernan M, Pamphlett R, Rowe D, Nicholson G, Kurth I, Hübner C, Ludolph A, Powell J, Logroscino G, Tortelli R, Pupillo E, Beghi E, Chio A, Casale F, Leigh P, Fifita J, Chandran S, Koritnik B, Ravnik-Glavač M, Vrabec K, Rogelj B, Lin K, Ticozzi N, Vajda A, Menelaou A, Medic J, Zidar J, Leonardis L, Polak M, Rojas-García R, Mora J, Pinto S, de Carvalho M, Meininger V, Salachas F, Millecamps S, Grošelj L, Brands W, Schellevis R, Robinson M, de Jong S, Vösa U, van der Spek R, Pulit S, Diekstra F, McLaughlin R, Dekker A, Shatunov A, Yang J, Fogh I, Harschnitz O, van Eijk K, Kenna K, Jones A, Sproviero W, Blokhuis A, Koppers M, Tazelaar G, van Doormaal P, van Rheenen W, Colville S, Cichon S, Maurel C, Andres C, Radivojkov-Blagojevic M, Lichtner P, Meitinger T, Parman Y, Hamzeiy H, Tunca C, Basak A, Bensimon G, Landwehrmeyer B, Rietschel M, Franke A, Lieb W, Tittmann L, Wood N, Dürr A, Saker-Delye S, Payan C, Brice A, McCluskey L, Elman L, Topp S, Malaspina A, Fratta P, Sidle K, Pittman A, Orrell R, Hardy J, Shaw P, Morrison K, Petri S, Abdulla S, Trojanowski J, Van Deerlin V, Lomen-Hoerth C, Wiedau-Pazos M, Staats K, Ophoff R, Meyer T, Sendtner M, Drepper C, Swingler R. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nat Genet* 2016; 48:1043-8.

Giulio D, Kamm C, Mattle H, Lotter C, Du Pasquier R, Schlupe M, Pot C, Lalive P, Yaldizli O, Gobbi C, Kappos L, Kuhle J, Louvion J, Derfuss T, Stippich C, Benkert P, Lorscheider J, Müller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue E, Sprenger T, SMSC Scientific Board. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. *PLoS one* 2016; 11:e0152347.

Gobbi C, Zecca C, Linnebank M, Müller S, You X, Meier R, Bortler E, Traber M. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies. *Eur Neurol* 2013; 70:35-41.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch